JP3278273B2
(ja)
*
|
1993-12-17 |
2002-04-30 |
キヤノン株式会社 |
薬剤徐放性カプセル
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
EP1365028B1
(en)
|
1996-12-13 |
2009-03-18 |
Novartis Vaccines and Diagnostics, Inc. |
Method for expression of PDGF or IGF proteins in yeast
|
US5985214A
(en)
|
1997-05-16 |
1999-11-16 |
Aurora Biosciences Corporation |
Systems and methods for rapidly identifying useful chemicals in liquid samples
|
EP2198854B1
(en)
|
1997-09-18 |
2011-11-30 |
Pacira Pharmaceuticals, Inc. |
Sustained-release liposomal anesthetic compositions
|
JP4472866B2
(ja)
|
1997-11-06 |
2010-06-02 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
ナイセリア抗原
|
ES2384094T3
(es)
|
1997-11-14 |
2012-06-29 |
Pacira Pharmaceuticals, Inc. |
Producción de liposomas multivesiculares
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
CN100379757C
(zh)
|
1998-05-01 |
2008-04-09 |
希龙公司 |
脑膜炎奈瑟球菌抗原和组合物
|
AU1316200A
(en)
|
1998-10-15 |
2000-05-01 |
Chiron Corporation |
Metastatic breast and colon cancer regulated genes
|
ES2310055T3
(es)
|
1998-12-16 |
2008-12-16 |
Novartis Vaccines & Diagnostic |
Quinasa humana dependiente de ciclina (hpnqalre).
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
JP2003518363A
(ja)
|
1999-04-30 |
2003-06-10 |
カイロン エセ.ピー.アー. |
保存されたナイセリア抗原
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
PT2275551E
(pt)
|
1999-10-29 |
2015-06-29 |
Novartis Vaccines & Diagnostic |
Péptidos antigénicos de neisseria
|
ES2335386T3
(es)
|
1999-11-18 |
2010-03-26 |
Novartis Vaccines And Diagnostics, Inc. |
Gen fgf-21 humano y productos de expresion genica.
|
AU784518B2
(en)
|
2000-01-17 |
2006-04-27 |
Glaxosmithkline Biologicals S.A. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
EP2075255A1
(en)
|
2000-03-08 |
2009-07-01 |
Novartis Vaccines and Diagnostics, Inc. |
Human FGF-23 gene and gene expression products
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
WO2001096523A2
(en)
|
2000-06-15 |
2001-12-20 |
Chiron Corporation |
Polynucleotides related to colon cancer
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
ES2397627T3
(es)
|
2000-12-07 |
2013-03-08 |
Novartis Vaccines And Diagnostics, Inc. |
Retrovirus endógenos regulados por aumento en el cáncer de próstata
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
US7309783B2
(en)
|
2001-05-09 |
2007-12-18 |
The University Of Connecticut |
Mammalian early developmental regulator gene
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
RU2316591C2
(ru)
|
2001-11-09 |
2008-02-10 |
Джорджтаун Юниверсити |
Новые изоформы ингибитора роста васкулярных эндотелиальных клеток
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
CA2472282A1
(en)
|
2002-01-08 |
2003-07-17 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
AU2003218350A1
(en)
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
CA2489292A1
(en)
|
2002-06-13 |
2003-12-24 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
EP2270048B1
(en)
|
2002-12-24 |
2015-11-11 |
Rinat Neuroscience Corp. |
Anti-NGF antibodies and methods using same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
PL379983A1
(pl)
|
2003-02-19 |
2006-11-27 |
Rinat Neuroscience Corp. |
Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
GB2388581A
(en)
|
2003-08-22 |
2003-11-19 |
Danisco |
Coated aqueous beads
|
US20070104809A1
(en)
|
2003-08-22 |
2007-05-10 |
Danisco A/S |
Composition comprising a bacteriocin and an extract from a plant of the labiatae family
|
KR20070001932A
(ko)
|
2003-12-23 |
2007-01-04 |
리나트 뉴로사이언스 코퍼레이션 |
작용물질 항 티알케이씨 항체 및 그의 사용 방법
|
CA2561696C
(en)
|
2004-03-29 |
2013-09-03 |
Galpharma Co., Ltd. |
Novel modified galectin 9 proteins and use thereof
|
KR101637908B1
(ko)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
WO2006085979A2
(en)
|
2004-07-09 |
2006-08-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of hendra and nipah virus g glycoprotein
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP1781704A2
(en)
|
2004-07-30 |
2007-05-09 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
DE05852057T1
(de)
|
2004-11-23 |
2007-11-29 |
Neuromolecular Pharmaceuticals Inc., Emeryville |
Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
WO2006058236A2
(en)
|
2004-11-24 |
2006-06-01 |
Neuromolecular Pharmaceuticals, Inc. |
Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
DK1874282T3
(da)
|
2005-04-06 |
2010-10-25 |
Adamas Pharmaceuticals Inc |
Fremgangsmåder og præparater til behandling af CNS lidelser
|
JP2008535494A
(ja)
|
2005-04-07 |
2008-09-04 |
サグレシュ ディスカバリー, インコーポレイテッド |
癌関連遺伝子(prlr)
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
BRPI0613770A2
(pt)
|
2005-07-22 |
2009-05-19 |
Y S Therapeutics Co Ltd |
anticorpos anti-cd26 e métodos de uso destes
|
PL2380592T3
(pl)
|
2005-11-14 |
2018-07-31 |
Teva Pharmaceuticals International Gmbh |
Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny
|
CA2637707A1
(en)
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corporation |
Methods for treating obesity by administering a trkb antagonist
|
JP5313886B2
(ja)
|
2006-06-07 |
2013-10-09 |
バイオアライアンス セー.フェー. |
癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP2134365B1
(en)
|
2007-03-21 |
2019-03-13 |
Effat Emamian |
Compositions and methods for inhibiting tumor cell growth
|
WO2008124176A2
(en)
|
2007-04-10 |
2008-10-16 |
The Administrators Of The Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP3587450A1
(en)
|
2007-12-17 |
2020-01-01 |
Pfizer Limited |
Treatment of interstitial cystitis with ngf inhibitors
|
NZ585959A
(en)
|
2007-12-18 |
2012-09-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
AU2009234389B2
(en)
|
2008-04-10 |
2014-08-21 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR mutations in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
CA3154626A1
(en)
|
2009-04-14 |
2010-10-21 |
Glaxosmithkline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
CA2767536A1
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
JP2012532626A
(ja)
|
2009-07-16 |
2012-12-20 |
ノバルティス アーゲー |
無毒化されたEscherichiacoli免疫原
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
JP5885668B2
(ja)
|
2009-12-02 |
2016-03-15 |
アダマス ファーマシューティカルズ, インコーポレイテッド |
アマンタジン組成物および使用方法
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
SG10201507722QA
(en)
|
2010-03-11 |
2015-10-29 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9770414B2
(en)
*
|
2010-05-13 |
2017-09-26 |
Pacira Pharmaceuticals, Inc. |
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
JP5936702B2
(ja)
|
2011-11-11 |
2016-06-22 |
ライナット ニューロサイエンス コーポレイション |
Trop−2に対して特異的な抗体およびこれらの使用
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
US9249224B2
(en)
|
2011-12-22 |
2016-02-02 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
AU2013286866B2
(en)
|
2012-07-02 |
2018-03-01 |
Commonwealth Scientific And Industrial Research Organization |
Paramyxovirus and methods of use
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
WO2014072876A1
(en)
|
2012-11-09 |
2014-05-15 |
Pfizer Inc. |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
CN105051068A
(zh)
|
2013-03-15 |
2015-11-11 |
戴埃克斯有限公司 |
抗血浆激肽释放酶抗体
|
WO2014181229A2
(en)
|
2013-05-07 |
2014-11-13 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR101809072B1
(ko)
|
2013-08-02 |
2017-12-14 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
TWI736515B
(zh)
|
2013-11-13 |
2021-08-21 |
美商輝瑞大藥廠 |
類腫瘤壞死因子之配體1a之專一性抗體及其組合物及用途
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
LT3119431T
(lt)
|
2014-03-21 |
2024-03-12 |
Teva Pharmaceuticals International Gmbh |
Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
|
US10308697B2
(en)
|
2014-04-30 |
2019-06-04 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
AU2016248946B2
(en)
|
2015-04-13 |
2022-03-10 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
CN108137705B
(zh)
|
2015-07-21 |
2022-11-08 |
武田药品工业株式会社 |
一种因子xiia的单克隆抗体抑制剂
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
CN107922506B
(zh)
|
2015-08-19 |
2021-11-09 |
辉瑞公司 |
组织因子途径抑制剂抗体及其用途
|
SI3350220T1
(sl)
|
2015-09-15 |
2021-12-31 |
Scholar Rock, Inc. |
Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh
|
JP6661319B2
(ja)
*
|
2015-09-28 |
2020-03-11 |
小林製薬株式会社 |
リポソーム
|
CA2946113A1
(en)
|
2015-10-23 |
2017-04-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
CN109069480A
(zh)
|
2015-12-30 |
2018-12-21 |
阿达玛斯医药公司 |
用于治疗与癫痫相关的病症的方法和组合物
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
CN109219618B
(zh)
|
2016-01-21 |
2022-08-09 |
辉瑞大药厂 |
针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
|
KR102069670B1
(ko)
*
|
2017-03-02 |
2020-01-23 |
단디바이오사이언스 주식회사 |
면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
|
EP3589657A1
(en)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
JP7177076B2
(ja)
|
2017-03-16 |
2022-11-22 |
ファイザー・インク |
チロシン原栄養性
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
WO2018200885A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Magnesium compositions and methods of use
|
MX2019014465A
(es)
|
2017-06-02 |
2020-01-23 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos.
|
EP3639170B1
(en)
|
2017-06-13 |
2021-03-24 |
BostonGene Corporation |
Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
|
CN110997002A
(zh)
|
2017-07-13 |
2020-04-10 |
麻省理工学院 |
靶向hdac2-sp3复合体以增强突触功能
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
AU2018344859A1
(en)
|
2017-10-04 |
2020-04-30 |
Hesperix SA |
Articles and methods directed to personalized therapy of cancer
|
MX2020008183A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos.
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
EP4414034A2
(en)
|
2018-05-23 |
2024-08-14 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
KR102584675B1
(ko)
|
2018-05-23 |
2023-10-05 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
CA3146077A1
(en)
|
2019-07-03 |
2021-02-18 |
Bostongene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
US20230287455A1
(en)
|
2020-07-30 |
2023-09-14 |
Pfizer Inc. |
Cells Having Gene Duplications and Uses Thereof
|
KR20230117327A
(ko)
|
2020-09-03 |
2023-08-08 |
어빈 에스.와이. 첸 |
가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
|
US20240029829A1
(en)
|
2020-12-04 |
2024-01-25 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
EP4330969A1
(en)
|
2021-04-29 |
2024-03-06 |
BostonGene Corporation |
Machine learning techniques for estimating tumor cell expression in complex tumor tissue
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023147177A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2024015561A1
(en)
|
2022-07-15 |
2024-01-18 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|